Standout Papers

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adeno... 2021 2026 2022 2024190
  1. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results (2021)
    Richard P. Baum, Christiane Schuchardt et al. Journal of Nuclear Medicine

Immediate Impact

1 from Science/Nature 36 standout
Sub-graph 1 of 16

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Pathology of pain and its implications for therapeutic interventions
2024 Standout
2 intermediate papers

Works of F Robiller being referenced

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
2021 Standout
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms
2018

Author Peers

Author Last Decade Papers Cites
F Robiller 112 115 265 130 9 337
Anne-Marie Marion-Audibert 35 145 213 140 15 365
Niklaus Schäfer 140 35 1 145 122 11 341
Rahel Sahli 30 141 124 188 12 391
C. Stoykow 183 18 129 73 14 344
Yaqing Dai 52 174 270 45 15 310
H.R. Marcuse 98 93 42 61 10 315
Katharina Lueckerath 113 143 302 38 15 354
François Thomas 36 29 82 111 12 305
W.T. Knöfel 38 165 190 90 7 386
Samaan Na 19 100 108 116 6 390

All Works

Loading papers...

Rankless by CCL
2026